https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2001-05-01 / Int. J. Oncol. 2001 May;18(5):945-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2001-05-01 / Int. J. Oncol. 2001 May;18(5):945-522001-05-01 00:00:002020-06-23 09:45:33Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2001-05-01 / J. Neurooncol. 2001 May;53(1):39-46
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2001-05-01 / J. Neurooncol. 2001 May;53(1):39-462001-05-01 00:00:002001-05-01 00:00:00Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2000-02-01 / J. Clin. Virol. 2000 Feb;16(1):1-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2000-02-01 / J. Clin. Virol. 2000 Feb;16(1):1-152000-02-01 00:00:002019-02-15 09:22:30Newcastle disease virus (NDV): brief history of its oncolytic strains
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1999-05-05 / JAMA 1999 May;281(17):1588-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1999-05-05 / JAMA 1999 May;281(17):1588-91999-05-05 00:00:002019-02-15 09:00:19Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1999-02-01 / Int. J. Oncol. 1999 Feb;14(2):205-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1999-02-01 / Int. J. Oncol. 1999 Feb;14(2):205-151999-02-01 00:00:002020-06-23 09:46:02Tumor stimulator cell modification by infection with Newcastle Disease Virus: analysis of effects and mechanism in MLTC-CML cultures
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1999-01-01 / Gene Ther. 1999 Jan;6(1):63-73
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1999-01-01 / Gene Ther. 1999 Jan;6(1):63-731999-01-01 00:00:002020-06-23 09:46:30Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1998-12-01 / Int. J. Oncol. 1998 Dec;13(6):1105-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1998-12-01 / Int. J. Oncol. 1998 Dec;13(6):1105-151998-12-01 00:00:002020-06-23 09:46:52Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1998-12-01 / Mol. Med. 1998 Dec;4(12):783-94
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1998-12-01 / Mol. Med. 1998 Dec;4(12):783-941998-12-01 00:00:001998-12-01 00:00:00A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1997-04-01 / J. Clin. Oncol. 1997 Apr;15(4):1354-66
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1997-04-01 / J. Clin. Oncol. 1997 Apr;15(4):1354-661997-04-01 00:00:002020-06-23 09:47:26Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1994-12-01 / Cancer Res. 1994 Dec;54(23):6017-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1994-12-01 / Cancer Res. 1994 Dec;54(23):6017-211994-12-01 00:00:001994-12-01 00:00:00Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy
